Disease Markers

The Discovery of Nucleotide and Nucleic Acid-Associated Biomarkers and Cancer Personalized Therapies


Publishing date
01 May 2022
Status
Closed
Submission deadline
31 Dec 2021

Lead Editor

1Xi'an Jiaotong University, Xi'an, China

2Jinan University, Guangzhou, China

3Augusta University, Augusta, USA

4University of Chicago, Chicago, USA

5University of Virginia, Charlottesville, USA

This issue is now closed for submissions.
More articles will be published in the near future.

The Discovery of Nucleotide and Nucleic Acid-Associated Biomarkers and Cancer Personalized Therapies

This issue is now closed for submissions.
More articles will be published in the near future.

Description

For half a century, cancer physicians have mainly relied on three primary treatment modalities: surgery, radiation therapy, and chemotherapy. Over that time, enormous progress has been made in understanding cancer biology. Targeted anti-cancer drugs have emerged, and thousands of clinical trials have taught us how to best craft treatment combinations that improve clinical outcomes.

However, each case of cancer exhibits a unique pathological signature and can be highly heterogeneous in response to the targeted therapeutic agents. Therefore, precise therapy is essential to improve cancer treatment. The development of personalized and rationalized therapy relies on the identification of the specific biomarkers, the validation of therapeutic targets, and the development of drugs against the validated targets. Nucleotide and Nucleic acid-associated biomarkers cover nucleotides, circulating cell-free DNA (cfDNA), circulating tumor DNA (ctDNA), mRNA, microRNAs (miRNAs), circular RNA (circRNA), exosomal RNAs (exRNAs), and long non-coding RNAs (IncRNAs) in tumor cells and serum. They are playing vital roles as diagnostic or therapeutic agents for cancer theranostics and can be used for cancer risk assessment, diagnosis, prognosis, and for the prediction of treatment efficacy and recurrence. In addition, the sensitive biomarkers can be also used as therapeutic targets for various tumors. Therefore, there is an urgent need to identify novel biomarkers and explore the biological functions of these biomarkers in order to greatly improve the clinical targeted therapies and immunotherapies of cancers.

This Special Issue aims to focus on the advances in the discoveries of nucleotide and nucleic acid-associated cancer biomarkers that inform treatment outcomes, including technologies and experimental approaches, as well as clinical validations and applications. We welcome the submission of original research and review articles.

Potential topics include but are not limited to the following:

  • New technologies or methods employed in characterizing molecular features of nucleotide and nucleic acid-associated biomarkers
  • cfDNA or ctDNA as biomarkers for cancer theranostics
  • circRNA, lncRNA, miRNA, or exRNAs as biomarkers for cancer theranostics
  • Regulatory roles of IncRNAs in tumorigenesis
  • The molecular mechanisms involved in the dysregualtion of nucleotide and nucleic acid-associated biomarkers in normal and pathological conditions
  • Nucleic acid-related biomarkers to predict the chemotherapy or immunotherapy response in cancer patients
  • Nucleotide regulation and metabolism in cancers
  • Other new emerging areas involving in nucleotide and nucleic acid-associated biomarkers, such as cross-analysis of biomarkers with nanomedicine, molecular imaging, omics data, etc.

Articles

  • Special Issue
  • - Volume 2022
  • - Article ID 8605621
  • - Research Article

Inhibition of miR-let-7i Induces DC Immature Cells and Improves Skin Graft Tolerance

Zhibin Zheng | Yurou Yang | ... | Peng Chen
  • Special Issue
  • - Volume 2022
  • - Article ID 5186252
  • - Research Article

Inhibition of miR-421 Preserves Mitochondrial Function and Protects against Parkinson’s Disease Pathogenesis via Pink1/Parkin-Dependent Mitophagy

Xiaolin Dong | Xianghua He | ... | Yanming Xu
  • Special Issue
  • - Volume 2022
  • - Article ID 3042105
  • - Research Article

Study on Circulating lncRNA Expression Profile in Patients with Cerebral Infarction

Man-tang Li | Cheng-hong Luo | ... | Ya Jin
  • Special Issue
  • - Volume 2022
  • - Article ID 2883029
  • - Research Article

Neuron-Specific Enolase and Hemoglobin as Risk Factors of Intraocular Metastasis in Patients with Renal Cell Carcinoma

Qiu-Yu Li | Ting Su | ... | Yi Shao
  • Special Issue
  • - Volume 2022
  • - Article ID 4586198
  • - Research Article

SIRT2 Affects Cell Proliferation and Apoptosis by Suppressing the Level of Autophagy in Renal Podocytes

Shuang Liu | Xiangfu Gao | ... | Qiao Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 9087190
  • - Research Article

Deubiquitination of TNKS1 Regulates Wnt/β-Catenin to Affect the Expression of USP25 to Promote the Progression of Glioma

Bin Tang | Hai Luo | ... | Jun Fu
  • Special Issue
  • - Volume 2022
  • - Article ID 7765900
  • - Research Article

Identification of Five N6-Methylandenosine-Related ncRNA Signatures to Predict the Overall Survival of Patients with Gastric Cancer

Qingfang Yue | Yuan Zhang | ... | Haipeng Wang
  • Special Issue
  • - Volume 2022
  • - Article ID 4317480
  • - Research Article

lncRNA CDKN2B-AS1 Could Be an Indicator to Identify Prognosis and Status of Immune Microenvironment in Thyroid Cancer

Cheng Xue | Cheng Yi | ... | Yisha Zhao
  • Special Issue
  • - Volume 2022
  • - Article ID 2751696
  • - Research Article

High Expression of MicroRNA-200a/b Indicates Potential Diagnostic and Prognostic Biomarkers in Epithelial Ovarian Cancer

Beilei Zhang | Yi Li | ... | Ruifang An
  • Special Issue
  • - Volume 2022
  • - Article ID 8920926
  • - Research Article

Diagnostic Value and Prognostic Evaluation of Autophagy-Related Protein Expression Level in Sepsis Complicated with Acute Respiratory Distress Syndrome

Jia-Li Xu | Xue-Lu Yu | ... | Mei Jing
Disease Markers
 Journal metrics
See full report
Acceptance rate23%
Submission to final decision60 days
Acceptance to publication23 days
CiteScore4.700
Journal Citation Indicator0.720
Impact Factor3.464
 Submit

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.